IMI grant for research into pulmonary administration of new Beta-lactam antibiotics
The department of Pharmaceutical Technology and Biopharmacy (Prof. Erik Frijlink) of the Groningen Research Institute of Pharmacy (GRIP) has received a 422K€ grant from EU’s Innovative Medicines Initiative (IMI). The “Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis” (iABC) project aims at the development of new antibiotics to be used in pulmonary diseases. The consortium consists of 19 partners from 7 countries. These groups combine experience and proven expertise and success in microbiology, antibiotic development, clinical trials, endpoints and patient registries. The activities in Groningen will focus on the development of formulations and devices for pulmonary administration of new Beta-lactam antibiotics.
IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
| Last modified: | 12 March 2015 12.04 p.m. |
More news
-
16 April 2024
UG signs Barcelona Declaration on Open Research Information
In a significant stride toward advancing responsible research assessment and open science, the University of Groningen has officially signed the Barcelona Declaration on Open Research Information.
-
02 April 2024
Flying on wood dust
Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...
-
18 March 2024
VentureLab North helps researchers to develop succesful startups
It has happened to many researchers. While working, you suddenly ask yourself: would this not be incredibly useful for people outside of my own research discipline? There are many ways to share the results of your research. For example, think of a...